Yagura T, Kamisaki Y, Wada H, Yamamura Y
Int Arch Allergy Appl Immunol. 1981;64(1):11-8.
For the successful administration of exogenous proteins and enzymes for therapeutic purposes, abrogation or modifications of antigenicity and immunogenicity of the protein must be achieved without substantial loss of the biological activity necessary for therapeutic purposes. In order to try this, a model experiment was carried out in the present study. Escherichia coli L-asparaginase, whose chemical properties have been well defined and which is used for the treatment of acute lymphocytic leukemia and malignant lymphomas, was modified by copolymerization with isologous albumin, and alterations of its immunogenicity were examined in mice. The results demonstrated that the immunogenicity of the modified L-asparaginase was remarkably reduced and satisfactory enzyme activity was preserved.
为了成功地将外源性蛋白质和酶用于治疗目的,必须消除或改变蛋白质的抗原性和免疫原性,同时又不大量丧失治疗所需的生物活性。为了尝试这一点,本研究进行了一项模型实验。化学性质已明确界定且用于治疗急性淋巴细胞白血病和恶性淋巴瘤的大肠杆菌L-天冬酰胺酶,通过与同源白蛋白共聚进行修饰,并在小鼠中检测其免疫原性的改变。结果表明,修饰后的L-天冬酰胺酶的免疫原性显著降低,同时保留了令人满意的酶活性。